Bruns, Tony

Effects of antibiotics on gut microbiota

Lange, K., Buerger, M., Stallmach, A., & Bruns, T. (2016) · Digestive Diseases

Gut microbiota and healthGastrointestinal motility and disorders

Cited by 607

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase

Murillo Perez, C. F., Harms, M. H., Lindor, K. D., van Buuren, H. R., Hirschfield, G. M., Corpechot, C., van der Meer, A. J., Feld, J. J., Gulamhusein, A., Lammers, W. J., et al. (2020) · American Journal of Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 188

Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response

Trivedi, P. J., Bruns, T., Cheung, A., Li, K.-K., Kittler, C., Kumagi, T., Shah, H., Corbett, C., Al-Harthy, N., Acarsu, U., et al. (2014) · Journal of Hepatology

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 132

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

Corpechot, C., Carrat, F., Gaouar, F., Chau, F., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Schramm, C., Pares, A., et al. (2022) · Journal of Hepatology

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 128

Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

Murillo Perez, C. F., Fisher, H., Hiu, S., Kareithi, D., Adekunle, F., Mayne, T., Malecha, E., Ness, E., van der Meer, A. J., Lammers, W. J., et al. (2022) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 107

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

Corpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 94

Milder disease stage in patients with primary biliary cholangitis over a 44‐year period: A changing natural history

Murillo Perez, C. F., Goet, J. C., Lammers, W. J., Gulamhusein, A., van Buuren, H. R., Ponsioen, C. Y., Carbone, M., Mason, A., Corpechot, C., Invernizzi, P., et al. (2018) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 88

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

Murillo Perez, C. F., Ioannou, S., Hassanally, I., Trivedi, P. J., Corpechot, C., van der Meer, A. J., Lammers, W. J., Battezzati, P. M., Lindor, K. D., Nevens, F., et al. (2023) · Liver International

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 39

Tissue-resident and innate-like T cells in patients with advanced chronic liver disease

Ibidapo-Obe, O., & Bruns, T. (2023) · JHEP Reports

Liver physiology and pathologyLiver Diseases and Immunity

Cited by 25